ABSTRACT
Heterotopic ossification (HO) frequently occurs after brain injury. Recently, we found that leptin levels were decreased in the serum of patients with HO. Data suggest two mechanisms mediating leptin effects: a central suppressive mechanism acting via the beta(2)-adrenergic system and a direct stimulatory action starting when leptin binds to its receptors in osteoblastic cells. In this study, we analyzed leptin and beta(2)-adrenergic receptors mRNA expression in osteocytes originated from normal or heterotopic bone biopsies to investigate whether direct or indirect pathway signaling might be implicated in this pathological bone formation. We report for the first time the mRNA expression of the leptin receptor isoforms in osteocytes isolated from all biopsies. Moreover, quantitative reverse transcription-polymerase chain reaction allowed us to measure a significant decrease in the level of beta(2)-adrenergic receptor mRNA in cells isolated from heterotopic bone biopsies. These results could suggest an association between hypothalamic leptin signaling and brain injury-related HO.
Subject(s)
Brain Injuries/complications , Leptin/blood , Ossification, Heterotopic/metabolism , Osteocytes/metabolism , Receptors, Adrenergic, beta-2/metabolism , Receptors, Leptin/metabolism , Adult , Brain Injuries/metabolism , Female , Gene Expression , Humans , Male , Middle Aged , Ossification, Heterotopic/etiology , Osteocytes/cytology , Proto-Oncogene Proteins c-fos/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, Adrenergic, beta-2/genetics , Receptors, Leptin/geneticsABSTRACT
Runx2 is a key regulator of osteoblast-specific gene expression and controls the expression of multiple target genes during osteoblast differentiation. Although some transcriptional targets for Runx2 are known, it is believed that the osteogenic action of Runx2 is mediated by additional target genes, and increasing studies are performed in order to identify such Runx2-responsive genes. To identify genes following the inhibition of Runx2 in osteoblastic cell line, SaOs-2 was stably transfected with a dominant negative mutant of Runx2 (Deltacbfa1) under the control of a strong promoter. Comparison of gene expression patterns by differential display on selected SaOs-2 clones allowed us to observe that GNAS mRNA which encodes for the Gsalpha protein is overexpressed (5 to 8 fold) in cells presenting high levels of Deltacbfa1. This overexpression was also observed at the protein level and seemed to be reflected by an increased basal cAMP level. Gel shift experiments performed in this study indicate that Runx2 is able to bind to the promoter of GNAS, suggesting a direct regulation at the transcriptional level. Well-described GNAS mutations like fibrous dysplasia or Albright hereditary osteodystrophy are linked to abnormality in osteoblast function, and numerous evidences showed that Gsalpha coupled adrenergic receptors increase the expression of osteotrophic factors and regulate bone mass. Regulation of Gsalpha protein by Runx2 seems to be of particular interest considering the increasing evidences on bone metabolism regulation by G proteins.
Subject(s)
Core Binding Factor Alpha 1 Subunit/metabolism , GTP-Binding Protein alpha Subunits, Gs/metabolism , Gene Expression Regulation , Animals , Base Sequence , Binding Sites , Cell Line, Tumor , Cell Nucleus/genetics , Cell Nucleus/metabolism , Chromogranins , Collagen Type I/genetics , Core Binding Factor Alpha 1 Subunit/genetics , Core Binding Factor Alpha 1 Subunit/isolation & purification , Cyclic AMP/metabolism , Humans , Mice , Molecular Sequence Data , Promoter Regions, Genetic/genetics , RNA, Messenger/geneticsABSTRACT
Current knowledge about mechanisms controlling osteoblast-specific gene expression has led to the identification of Cbfa1 as a key regulator of osteoblast differentiation. Several essential questions about this transcription factor remain to be addressed, e.g., the nature of stimuli that may modulate its own expression, as well as the genetic repercussions following alterations in Cbfa1 levels. To identify such Cbfa1-responsive genes, the SaOs-2 cell line was stably transfected with a dominant negative mutant of Cbfa1 (DeltaCbfa1). Comparison of gene expression patterns by differential display on selected SaOs-2 clones allowed the identification of four new genes that may be under the control of Cbfa1. Three of them, SelM, elF-4AI, and RPS24, seemed to be linked to a global change in cellular metabolism and cell growth. The fourth, the CD99/MIC2 gene, was strongly overexpressed (around tenfold) in cells presenting high levels of Deltacbfa1. This observation adds evidence to show that this marker of Ewing family tumors is linked to the osteoblast lineage. The exact function of CD99 remains largely undefined, and this is the first time that its regulation by an essential transcription factor involved in osteoblast differentiation has been observed.
Subject(s)
Neoplasm Proteins/genetics , Osteosarcoma/genetics , Transcription Factors/genetics , 12E7 Antigen , Antigens, CD/biosynthesis , Cell Adhesion Molecules/biosynthesis , Cell Line, Tumor , Clone Cells/metabolism , Core Binding Factor Alpha 1 Subunit , Eukaryotic Initiation Factor-4A/biosynthesis , Humans , Osteoclasts/metabolism , Osteosarcoma/metabolism , Polymerase Chain Reaction , Proteins/metabolism , Ribosomal Proteins/biosynthesis , Selenoproteins , Signal Transduction/genetics , Transfection , Up-RegulationABSTRACT
Heterotopic ossification (HO), a possible complication of head injury, develops in sites where it is not normally present like at the vicinity of joints. It may cause pain, decrease motion and in severe cases complete joint ankylosis requiring surgical intervention. To our knowledge, no study has been made to analyze HO at the molecular level on human biopsies, whereas its etiology remains to be determined. We defined a procedure of cell fractionation from bone resections and developed quantitative RT-PCR to compare genetic expression patterns between human normal osteoblasts and heterotopic ossification forming cells. This quantitative study demonstrated a specific and strong overexpression of osteocalcin mRNA in HO-isolated cells associated with a significant upregulation of type 1 collagen and osteonectin mRNA while histological analysis showed only small cellular variations. Our results give a first molecular characterization of heterotopic ossification and we conclude that such overexpressions in HO-isolated cells could be associated with the high activity of this pathological bone.
Subject(s)
Gene Expression , Ossification, Heterotopic/metabolism , Osteoblasts/metabolism , Osteocalcin/genetics , Osteocalcin/metabolism , Osteogenesis/genetics , Adult , Collagen Type I/genetics , Collagen Type I/metabolism , Female , Humans , Male , Middle Aged , Ossification, Heterotopic/genetics , Osteoblasts/cytology , Osteonectin/genetics , Osteonectin/metabolism , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Up-RegulationABSTRACT
The influence of culture conditions on the extracellular matrix (ECM) protein expressions of rabbit bone marrow stromal cells has been studied. The focus was on the effects of two kinds of sera, fetal calf serum (FCS) and Ultroser, on cells treated with dexamethasone. The induction of osteoblastic differentiation by dexamethasone addition is confirmed, particularly when cells are cultured in FCS. Bone marrow stromal cells produce alkaline phosphatase positive CFU-F and produce ECM with some mineralized nodules. Analysis by means of two-dimensional gel electrophoresis showed important changes in the composition of ECM proteins after dexamethasone treatment. Overexpression, underexpression, and new synthesized proteins were observed. The most significant modification was linked to the synthesis of four new proteins visible in the acidic area with a low molecular weight of around 17 kDa. These proteins did not correspond to those ECM proteins known to be induced by dexamethasone. Moreover, the effect of dexamethasone on osteoblastic differentiation induction appears very limited when cells are cultured in Ultroser compared to FCS. The protein pattern with Ultroser is different to that obtained with FCS. Cells cultured in Ultroser synthesized no new protein. The different behavior of cells according to the type of medium used is discussed in terms of the osteogenic factors present in the two different sera.
Subject(s)
Extracellular Matrix Proteins/metabolism , Osteoblasts/metabolism , Animals , Bone Marrow Cells , Cell Culture Techniques/methods , Cell Differentiation/drug effects , Culture Media/pharmacology , Dexamethasone/pharmacology , Electrophoresis, Gel, Two-Dimensional , Extracellular Matrix Proteins/analysis , Extracellular Matrix Proteins/drug effects , Female , Proteins/analysis , Rabbits , Stem Cells/cytology , Stromal Cells/cytologyABSTRACT
For the clinical application of cultured human mesenchymal stem cells (MSCs), cells must have minimal contact with fetal calf serum (FCS) because it might be a potential vector for contamination by adventitious agents. The use of human plasma and serum for clinical applications also continues to give rise to considerable concerns with respect to the transmission of known and unknown human infectious agents. With the objective of clinical applications of cultured human MSCs, we tested the ability of autologous plasma, AB human serum, FCS, and artificial serum substitutes containing animal-derived proteins (Ultroser G) or vegetable-derived proteins (Prolifix S6) to permit their growth and differentiation in vitro. To conserve as much autologous plasma as possible, we attempted to mix it at decreasing concentrations with the serum substitute containing vegetable-derived mitogenic factors. Under control conditions, by day 10 all the fibroblast colony-forming units (CFU-Fs) were alkaline phosphatase (ALP) positive. However, their number and size were highly variable among donors. Better CFU-F formation was obtained with Ultroser G, and with human AB serum and autologous plasma mixed at, respectively, 5 and 1% with Prolifix S6. The effects of these mixtures on CFU-F formation demonstrate synergy, with the human serum or plasma supplying the factors that favor differentiation of MSCs while Prolifix S6 supplies the mitogenic factors. Finally, we demonstrated the possibility of controlling human MSC growth and differentiation in vitro. Notably, by means of a minimal quantity of human serum or human plasma mixed with a new serum substitute containing vegetable-derived proteins, we displayed growth and differentiation of human MSCs comparable to that obtained with FCS or serum substitutes containing animal-derived proteins. These results will have crucial significance for future applications of cultured human MSCs in bone tissue engineering.